» Articles » PMID: 33276369

Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques

Abstract

Recent studies have reported the protective efficacy of both natural and vaccine-induced immunity against challenge with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques. However, the importance of humoral and cellular immunity for protection against infection with SARS-CoV-2 remains to be determined. Here we show that the adoptive transfer of purified IgG from convalescent rhesus macaques (Macaca mulatta) protects naive recipient macaques against challenge with SARS-CoV-2 in a dose-dependent fashion. Depletion of CD8 T cells in convalescent macaques partially abrogated the protective efficacy of natural immunity against rechallenge with SARS-CoV-2, which suggests a role for cellular immunity in the context of waning or subprotective antibody titres. These data demonstrate that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune responses may contribute to protection if antibody responses are suboptimal. We also show that higher antibody titres are required for treatment of SARS-CoV-2 infection in macaques. These findings have implications for the development of SARS-CoV-2 vaccines and immune-based therapeutic agents.

Citing Articles

Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients.

Debie Y, Garcia-Fogeda I, Willem L, Roelant E, Verbruggen L, Vanhoutte G Sci Rep. 2025; 15(1):7858.

PMID: 40050359 PMC: 11885447. DOI: 10.1038/s41598-025-92254-8.


Increased SARS-CoV-2 IgG4 has variable consequences dependent upon Fc function, Fc receptor polymorphism, and viral variant.

Aurelia L, Purcell R, Theisen R, Kelly A, Esterbauer R, Ramanathan P Sci Adv. 2025; 11(9):eads1482.

PMID: 40009690 PMC: 11864192. DOI: 10.1126/sciadv.ads1482.


Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes.

Simonson A, Zeppa J, Bucsan A, Chao M, Pokkali S, Hopkins F J Exp Med. 2025; 222(4).

PMID: 39912921 PMC: 11801270. DOI: 10.1084/jem.20241571.


Effect of Homologous and Heterologous Booster in COVID-19 Vaccination.

Vukcevic M, Despot M, Nikolic-Kokic A, Blagojevic D, Nikolic M, Banko A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770576 PMC: 11679259. DOI: 10.3390/ph17121734.


Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.

Lykins W, Pollet J, White J, Keegan B, Versteeg L, Strych U Front Immunol. 2024; 15:1480976.

PMID: 39737197 PMC: 11683073. DOI: 10.3389/fimmu.2024.1480976.